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The patients diagnosis and the type of their new malignancy
NO. Primary Diagnosis
New
Malignancy
Days till new
malignancy
1 MDS Lymphoma 954
2 AML-M4 Lymphoma 282
3 AML-M2 Lymphoma 594
4
NHL Small non clear cell,
Burkit Gastric cancer 451
5
NHL Large cell anaplastic
Lymphoma, Ki 1  CML 31
6 Fanconi Anemia Lymphoma 301
7 CML Ph1 , BCR ABL  Lymphoma 165
8
CML Ph1 , BCR ABL
unknown ALL 83
Table N.1
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A NEW CONDITIONING REGIMEN IN THALASSEMIA MAJOR CLASS 3 AN
EXPERIENCE OF IRAN FROM 2004 TILL 2006
Iravani, M.1, Alimogaddam, K.1, Khatami, F.1, Jalili, M.1,
Tagipur, R.1, Bab hadiashar, N.1, Gaffari, F.1, Mousavi, A.1,
Jahani, M.1, Bahar, B.1, Khodabandelu, Gavamzadeh, A.1 1Hematol-
ogy-Oncology and BMT Research Center, Tehran University of Medical
Sciences, Tehran, Islamic Republic of Iran.
Objective: Resent studies have showed the efﬁcacy of Fludarabin
(Flu) and Busulfan (BU) as a conditioning regimen in senile and
high risk leukemia patients. This regimen has good safety proﬁle
and transplant related complication such as cardiopulmonary and
liver dysfunction is venial. We used Flu (40 mg/m2/4 days) and Bu
(4mg/kg/4days) for patients who are at risk of rejection, Graft
Versus Host Disease (GVHD) and cardiopulmonary complications
(Thalassemia class 3) as myeloablative conditioning regimen for
HLA match sibling allogeneic stem cell transplantation.
Methods: Since August 2004 till September 2006, six patients
with Thalassemia class III received blood and marrow transplan-
tation from their HLA-identical siblings. One patient received
bone marrow and ﬁve patients received peripheral blood stem cell
transplantation. Conditioning regimen was Flu 40 mg/m2 (from
day–6 to -2) and Busulfan 4 mg/kg/day (from day –5 to -2).
GVHD prophylaxis regimen was cyclosporine.A 3mg/kg /day/IV
(days –3, 7), then 12.5 mg/kg/day/PO.
Results:Median age at time of transplantation was 19 years (Age
range: 11-26.5), Male/Female:5/1. Median Mononucleated cells
were 5.02/kg  108 and median CD34 was 2%. Median time of
absolute neutrophil count 0.5109 /L was20 and Median time
of platelet recovery 20109 /L was 31. Two patients (33.3%)
developed acute GVHD (grade I: 1, grade III: 1) and three patients
(50%) developed chronic GVHD (limited). Three patients (50%)
had Mocusitis and two ones (33.3%) had Nutropenic fever and
three patients had elevated liver enzymes. Till now all patients are
alive and we have just one relapse.
Conclusion: According to this study Flu/BU as a conditioning
regimen is safe and effective in Thalassemia class 3 patients.
Key Words: Blood and marrow transplantation, Thalassemia
class 3.
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LATE EFFECTS IN SURVIVORS OF HODGKIN’S AND NON-HODGKIN’S
LYMPHOMA TREATED WITH AUTOLOGOUS HEMATOPOIETIC CELL
TRANSPLANTATION: A REPORT FROM THE BONE MARROW TRANS-
PLANT SURVIVOR STUDY
Majhail, N.S.1, Ness, K.K.1, Burns, L.J.1, Carter, A.2, Francisco, L.2,
Sun, C.-L.2, Forman, S.J.2, Bhatia, S.2, Baker, K.S.1 1University of Min-
nesota, Minneapolis, MN; 2City of Hope Cancer Center, Duarte, CA.
We conducted a retrospective cohort study to evaluate late effects of
autologous hematopoietic cell transplantation (HCT) in Hodgkin’s
lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) survivors.
Eligible subjects received HCT at either City of Hope or University
of Minnesota between 1974 and 1998, were 18 years or older at the
time of interview and had survived for 2 years or more after HCT. A
random sample of siblings of study participants was recruited for
comparison. All participants (n92 HL, n184 NHL, n319 sib-
lings) completed a 238 item questionnaire. Median age at HCT was
39 years (range, 13-69) and median followup was 6 years (range, 2-17)
since HCT. Median age at completion of survey was 46 years (range,
21-73) for HCT survivors and 44 years (range, 19-79) for siblings.
Patient characteristics were similar between HL and NHL groups
except a higher proportion of NHL survivors received total body
irradiation (TBI) as part of their conditioning (83% vs 40%). Com-
pared to siblings (after adjusting for age at interview and sex), HCT
survivors reported a signiﬁcantly higher frequency of cataracts (14%
vs 4%), dry mouth (14% vs 1%), hypothyroidism (19% vs 7%), bone
impairments (osteoporosis and avascular necrosis) (7% vs 3%), con-
gestive heart failure (4% vs 0.3%), exercise induced shortness of
breath (10% vs 3%), neurosensory impairments (33% vs 20%), sec-
ond cancers (8% vs 2%), and inability to attend work or school due to
health impairments (16% vs 2%). 84% subjects rated their overall
health as good, very good or excellent compared to 95% siblings
(p0.001). Multivariate models adjusted for age at HCT and time
since HCT simultaneously considered the effects of sex, diagnosis
(HL vs. NHL) and conditioning regimen (TBI vs. no TBI). Com-
pared to those receiving no TBI, patients treated with TBI based
conditioning had higher risks of cataracts (odds ratio (OR) 4.9, 95%
CI: 1.5-15.5) and dry mouth (OR 3.4, 95%CI: 1.1-10.4). Females had
a greater likelihood of reporting hypothyroidism (OR 2.5, 95% CI:
1.3-4.7), osteoporosis (OR 8.7, 95% CI: 1.8-41.7), congestive heart
failure (OR 4.3, 95% CI: 1.1-17.2) and abnormal balance, tremor or
weakness (OR 2.4, 95% CI: 1.0-5.5). In conclusion, HL and NHL
survivors of autologous HCT have a high prevalence of long-term
health-related complications and require continued monitoring for
late effects with timely introduction of appropriate interventions.
133
5 CASES OF PERMANENT ALOPECIA AFTER VARIOUS CONDITIONING
REGMIENS COMMONLY USED IN BONE MARROW TRANSPLANTATION
Machado, M.1, Moreb, J.1, Khan, S.A.1 1University of Florida College
of Medicine, Department of Medicine, Division of Hematology/Oncology,
Gainesville, FL.
Alopecia, a common side effect of chemotherapy, is usually tempo-
rary and reversible within few months. Irreversible alopecia has been
reported (36 patients in 5 reports) after high dose chemotherapy
(HDC) and hematopoetic stem cell transplantation (HSCT) espe-
cially related to busulfan and cyclophosphamide containing condition-
ing regimens; however the overall incidence is not known. We de-
scribe 5 patients who experienced permanent alopecia after HSCT
including 2males and 3 females.Median age at transplant was 43 years
(Range 37-55), 3 were Caucasians and 2 African American. Diagnosis
included: Ewing sarcoma (1), multiple myeloma (2), CML (1) and
AML (1). Three patients received autologous peripheral blood stem
cell transplant (ASCT) one of them had tandem transplant, one
underwent matched sibling allogeneic transplant and one received
umbilical cord blood transplant. Total of 760 transplants were per-
formed in our institution during that period (1997-2004). Condition-
ing regimens included BuCyVP16 (busulfan, cyclophosphamide and
etoposide) in 2 patients, one of these patients received 2nd ASCT with
CyTBI, BuCy (2 patients) and CyVP16TBI (1 patient). Patients were
followed in our outpatient clinic with median follow up from last
transplant of 40 months (Range 19 to 58 months). Two of the females
and one of the male patients had complete alopecia, while the other
male and female had alopecia areata. In all ﬁve cases however, there
was no re-growth of hair. In one patient who received BuCy, there
was evidence of chronic graft vs host disease which had completely
resolved after 6 mos treatment. The current disease status is complete
remission (3), and partial remission in two patients with multiple
myeloma. All patients received Cy, 4 received Bu, three had VP-16
and 2 patients had TBI containing combinations. This data shows that
permanent alopecia is a signiﬁcant long-term side effect of HSCT and
can be seen across the spectrum of diseases and transplant types. Our
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